Tolvaptan for treating autosomal dominant polycystic kidney disease - guidance (TA358)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
28 October 2015

Abstract

Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults. 

Guidance development process 

How we develop NICE technology appraisal guidance 

Next review date: October 2018